MULTIPLEX ANALYSIS OF BIOMARKERS OF NEOANGIOGENESIS AND INFLAMMATION IN HEART TRANSPLANT RECIPIENTS

Aim of study: multiplex analysis of the levels of biomarkers of neoangiogenesis and inflammation in cardiac transplant recipients.
Materials and methods. 59 pts. with heart failure III–IV according to NYHA FC, waiting for a heart transplant, aged 22 to 73 years, 48 males and 11 females. 41 recipient (30 men and 11 women) had dilated cardiomyopathy, 18 – coronary heart disease (CHD). The concentration of VEGF-A, VEGF-D, PlGF, PDGF-BB, FGF, sCD40L, MCP-1 was measured using xMAP technology, the sets of reagents Simplex ProcartaPlexTM (Affymetrix, USA).
Results. There are four levels of seven biomarkers of neoangiogenesis and inflammation method for multiplex analysis in patients with heart failure. A year after transplantation, the mean levels of biomarkers VEGF-A (p = 0.001), PDGF-BB (p = 0.018), MCP-1 (p = 0.003) was significantly decreased, and the others had a tendency to decrease relative to the level before transplantation. It was shown individual differences of levels of VEGF-A, VEGF-D and PlGF before and after transplantation. There were found different dynamics of the concentrations of biomarkers and growth factors before and after heart transplantation in patients with cardiovascular complications and without them.
Conclusion. Multiplex analysis allows to measure the concentration range of analyte biomarkers of neoangiogenesis, inflammation in one sample of blood serum of patients with severe heart failure and after transplantation. There are marked individual differences in the concentration of biomarkers in different clinical situations that may have clinical significance in the conduct and supervision of recipients after transplantation.

1. Zimmer RJ, Lee MS. Transplant coronary artery disease. JACC Cardiovasc Interv. 2010; 3: 367–377.

2. Lund LH, Edwards LB, Kucheryavaya AY, Dipchhand AI, Benden C, Christie JD et al. The registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report – 2013; Focus Theme: Age. J Heart Lung Transplant. 2013; 32 (10): 951–964.

3. Шевченко АО. Новые лабораторные маркеры ангиогенеза и повреждения атеросклеротической бляшки. Клиническая лабораторная диагностика. 2006; 6: 23–34. Shevchenko AO. Novye laboratornye markery angiogeneza i povrezhdeniya ateroskleroticheskoy blyashki. Klinicheskaya laboratornaya diagnostika. 2006; 6: 23–34.

4. Martinez-Dolz L, Almenar L, Reganon E, Vila V, Sanchez-Soriano R, Martinez-Sales V et al. What is the best biomarker for diagnosis of rejection in heart transplantation? Clin. Transplant. 2009; 23: 672–680. doi: 10.1111/j.l399-0012.2009.01074.x.

5. Шумаков ВИ, Шевченко ОП, Хубутия МШ, Орлова ОВ, Казаков ЭН, Кормер АЯ, Олефиренко ГА. Васкулопатия трансплантированного сердца: синергизм провоспалительных, проатерогенных факторов и вирусной инфекции. Вестник Российской академии медицинских наук. 2006; 11: 8–14. Shumakov VI, Shevchenko OP, Khubutiya MSh, Orlova OV, Kazakov EN, Kormer AYa, Olefirenko GA. Vaskulopatiya transplantirovannogo serdtsa: sinergizm provospalitel'nykh, proaterogennykh faktorov i virusnoy infektsii. Vestnik Rossiyskoy akademii meditsinskikh nauk. 2006; 11: 8–14.

6. Daly KP, Seifert ME, Chandraker A, Zurakowski D, Nohria A, Givertz MM et al. VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. J. Heart. Lung. Transplant. 2013; 32 (1): 120–128.

7. Richter B, Koller L, Hohensinner PJ, Zorn G, Brekalo M, Berger R et al. A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. International Journal of Cardiology. 2013; 168 (2): 1251–1257.

8. Tait BD, Süsal C, Gebel HM, Nickerson PW, Zachary AA, Claas FHJ et al. Consensus guidelines on the testing and clinical management issues associated with HLA and Non-HLA antibodies in transplantation. Transplantation. 2013; 95 (1): 19–47.

9. Patel JK, Kobashigawa JA. Thoracic organ transplantation: Laboratory methods. Methods in Molecular Biology. 2013; 1034: 127–143.

10. Andrikopoulou E, Mather PJ. Current insights: Use of Immuknow in heart transplant recipients. Progress in Transplantation. 2014; 24 (1): 44–50.

11. Breen EJ, Polaskova V, Khan A. Bead-based multiplex immuno-assays for cytokines, chemokines, growth factors and other analytes: Median fluorescence intensities versus their derived absolute concentration values for statistical analysis. Cytokine. 2015; 71 (2): 188–198.

12. Escudero-Esparza A, Martin TA, Davies ML, Jiang WG. PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance. Cancer Genomics and Proteomics. 2009; 6 (4): 239–246.

13. Готье СВ, Иткин ГП, Шемакин СЮ, Саитгареев РШ, Попцов ВН, Захаревич ВМ и др. Первый опыт клинического применения отечественного аппарата вспомогательного кровообращения на базе имплантируемого осевого насоса для двухэтапной трансплантации сердца. Вестник трансплант. и искусств. органов. 2013; XV (3): 92–101. Gautier SV, Itkin GP, Shemakin SYu, Saitgareev RSh, Poptsov VN, Zakharevich VM et al. Pervyy opyt klinicheskogo primeneniya otechestvennogo apparata vspomogatel'nogo krovoobrashcheniya na baze implantiruemogo osevogo nasosa dlya dvukhetapnoy transplantatsii serdtsa. Vestnik transplant. i iskusstv. organov. 2013; XV (3): 92–101.